On June 2, Shake Shack issued a business update reflecting ongoing macroeconomic challenges and competitive pressures. The company provided insights into its fiscal second-quarter performance, emphasizing that while its fundamental business drivers remain strong, the current environment has necessitated an adjustment in guidance.
Malcolm Ethridge, managing partner at Capital Area Planning Group, named Morgan Stanley (NYSE:MS) as his final trade.
On May 8, Citigroup analyst Keith Horowitz maintained Morgan Stanley at Neutral and raised the price target from $170 to $194.
Don’t forget to check out our premarket coverage here
Jim Lebenthal, partner at Cerity Partners, picked AbbVie Inc. (NYSE:ABBV).
According to recent news, AbbVie, on May 29, announced European Commission authorization of an expanded label for VENCLYXTO® (venetoclax) to include additional combinations in previously untreated chronic lymphocytic leukemia.
Joseph M. Terranova, senior managing director for Virtus Investment Partners, recommended Cboe Global Markets, Inc. (NASDAQ:CBOE).
Price Action:
- Shake Shack shares gained 1.6% to close at $53.78 on Tuesday.
- Morgan Stanley shares fell 0.9% to settle at $210.25 during the session.
- AbbVie shares rose 1.1% to settle at $225.42 on Tuesday.
- Cboe Global Markets gained 3.7% on Tuesday.
Photo via Shutterstock